839 results on '"Caraglia A"'
Search Results
2. An innovative measure architecture to monitor civil infrastructures
- Author
-
Federico Germano, Alberto Rigon, and Francesco Caraglia
- Subjects
Earth-Surface Processes - Published
- 2023
3. Polydatin Induces Differentiation and Radiation Sensitivity in Human Osteosarcoma Cells and Parallel Secretion through Lipid Metabolite Secretion
- Author
-
Pilar Chacon Millan, Paola Stiuso, Stefania Lama, Salvatore Cappabianca, Angelo Sangiovanni, Carlo Caputo, Michele Caraglia, Pasquale Ferranti, Amalia Luce, Annalisa Itro, Luce, Amalia, Lama, Stefania, Millan, Pilar Chacon, Itro, Annalisa, Sangiovanni, Angelo, Caputo, Carlo, Ferranti, Pasquale, Cappabianca, Salvatore, Caraglia, Michele, Stiuso, Paola, Luce, A., Lama, S., Millan, P. C., Itro, A., Sangiovanni, A., Caputo, C., Ferranti, P., Cappabianca, S., Caraglia, M., and Stiuso, P.
- Subjects
musculoskeletal diseases ,0301 basic medicine ,Aging ,Ceramide ,Glucoside ,Article Subject ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Glucosides ,Downregulation and upregulation ,Stilbenes ,medicine ,Humans ,Secretion ,Osteosarcoma ,QH573-671 ,Bone cancer ,Mesenchymal stem cell ,Cell Differentiation ,Cell Biology ,General Medicine ,Lipid Metabolism ,medicine.disease ,Sphingolipid ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,Cytology ,Research Article ,Drugs, Chinese Herbal ,Human - Abstract
Osteosarcoma is a bone cancer characterized by the production of osteoid tissue and immature bone from mesenchymal cells. Osteosarcoma mainly affects long bones (femur is most frequently site) and occur in children and young adults with greater incidence. Here, we investigated the role accomplished by polydatin, a natural antioxidative compound, in promoting osteogenic differentiation alone or after radiation therapy on osteosarcoma cells. In vitro, polydatin significantly induced cell cycle arrest in S-phase and enhanced bone alkaline phosphatase activity. Moreover, the differentiation process was paralleled by the activation of Wnt-β-catenin pathway. In combination with radiotherapy, the pretreatment with polydatin promoted a radiosensitizing effect on osteosarcoma cancer cells as demonstrated by the upregulation of osteogenic markers and reduced clonogenic survival of tumor cells. Additionally, we analyzed, by mass spectrometry, the secretion of sphingolipid, ceramides, and their metabolites in osteosarcoma cells treated with polydatin. Overall, our results demonstrate that polydatin, through the secretion of sphingolipids and ceramide, induced osteogenic differentiation, alone and in the presence of ionizing therapy. Future investigations are needed to validate the use of polydatin in clinical practice as a potentiating agent of radiotherapy-induced anticancer effects.
- Published
- 2021
4. Early Estimates of Monkeypox Incubation Period, Generation Time, and Reproduction Number, Italy, May–June 2022
- Author
-
Giorgio, Guzzetta, Alessia, Mammone, Federica, Ferraro, Anna, Caraglia, Alessia, Rapiti, Valentina, Marziano, Piero, Poletti, Danilo, Cereda, Francesco, Vairo, Giovanna, Mattei, Francesco, Maraglino, Giovanni, Rezza, and Stefano, Merler
- Subjects
Male ,Microbiology (medical) ,Sexual and Gender Minorities ,Infectious Diseases ,Italy ,Epidemiology ,Reproduction ,Humans ,Monkeypox ,Homosexuality, Male ,Monkeypox virus ,Infectious Disease Incubation Period - Abstract
We analyzed the first 255 PCR-confirmed cases of monkeypox in Italy in 2022. Preliminary estimates indicate mean incubation period of 9.1 (95% CI 6.5-10.9) days, mean generation time of 12.5 (95% CI 7.5-17.3) days, and reproduction number among men who have sex with men of 2.43 (95% CI 1.82-3.26).
- Published
- 2022
5. Hypertension, type 2 diabetes, obesity, and p53 mutations negatively correlate with metastatic colorectal cancer patients’ survival
- Author
-
Ottaiano, Alessandro, Santorsola, Mariachiara, Circelli, Luisa, Perri, Francesco, Cascella, Marco, Sabbatino, Francesco, Capuozzo, Maurizio, Granata, Vincenza, Zappavigna, Silvia, Lombardi, Angela, Scrima, Marianna, Petrillo, Nadia, Ianniello, Monica, Casillo, Marika, Gualillo, Oreste, Nasti, Guglielmo, Caraglia, Michele, Savarese, Giovanni, Ottaiano, Alessandro, Santorsola, Mariachiara, Circelli, Luisa, Perri, Francesco, Cascella, Marco, Sabbatino, Francesco, Capuozzo, Maurizio, Granata, Vincenza, Zappavigna, Silvia, Lombardi, Angela, Scrima, Marianna, Petrillo, Nadia, Ianniello, Monica, Casillo, Marika, Gualillo, Oreste, Nasti, Guglielmo, Caraglia, Michele, and Savarese, Giovanni
- Subjects
p53 ,obesity ,hypertension ,NGS ,metastatic colorectal cancer ,prognosis ,type 2 diabetes ,General Medicine ,prognosi - Abstract
IntroductionWe studied the predictive and prognostic influences of hypertension (HT), type 2 diabetes (T2D), weight, and p53 mutations in metastatic colorectal cancer (CRC) patients.Patients and methodsT2D was diagnosed according to the ADA criteria. HT was classified according to the ACC/AHA guidelines. BMI (body-mass index) was calculated and classified according to the WHO criteria. TruSigt™Oncology 500 kit was applied to construct the genomic libraries for Next Generation Sequencing (NGS) analysis. The Illumina NovaSeq 6000 technological platform and the Illumina TruSight Oncology 500 bioinformatics pipeline were applied to analyze results. Overall survival (OS) was calculated through Kaplan-Meier curves. Univariate and multivariate analyses were performed to assess the relationships between clinical and/or molecular covariates. Associations between HT, T2D, BMI, p53, and clinical variables were evaluated by the χ2 test. P < 0.05 were considered statistically significant.ResultsTwo-hundred-forty-four patients were enrolled. One-hundred-twenty (49.2%), 110 (45.1%), and 50 (20.5%) patients were affected by overweight, HT, and T2D, respectively. DC (disease control) was achieved more frequently in patients without T2D (83.1%) compared to the diabetic ones (16.9%) (P = 0.0246). DC, KRAS mutational status, T2D, BMI, and concomitant presence of T2D, BMI, and HT associated with survival (P < 0.05). At multivariate analysis, age (≥65 vs. P = 0.0217) emerged as independent prognostic variables. P53 was mutated in 31/53 analyzed cases (60.4%). The most frequent gene variants were p.Arg175His and p.Cys135Tyr. High BMI (>25 kg/m2) associated with occurrence of p53 mutations (P < 0.0001). P53 mutated patients presented a worse prognosis compared to the wild-type ones (HR: 3.21; 95% CI: 1.43–7.23; P = 0.0047).ConclusionDiabetic, hypertensive and overweight metastatic CRC patients are a negative prognostic subgroup deserving specific therapeutic strategies. P53 mutations associate with prognosis and BMI unrevealing complex and unexplored connections between metabolism and cancer occurrence.
- Published
- 2023
- Full Text
- View/download PDF
6. Possible Effects of Uremic Toxins p-Cresol, Indoxyl Sulfate, p-Cresyl Sulfate on the Development and Progression of Colon Cancer in Patients with Chronic Renal Failure
- Author
-
Di Paola, Rossella, De, Ananya, Izhar, Raafiah, Abate, Marianna, Zappavigna, Silvia, Capasso, Anna, Perna, Alessandra F, La Russa, Antonella, Capasso, Giovambattista, Caraglia, Michele, Simeoni, Mariadelina, Di Paola, Rossella, De, Ananya, Izhar, Raafiah, Abate, Marianna, Zappavigna, Silvia, Capasso, Anna, Perna, Alessandra F, La Russa, Antonella, Capasso, Giovambattista, Caraglia, Michele, and Simeoni, Mariadelina
- Subjects
colon cancer ,p-cresol ,chronic renal failure ,dysbiosi ,p-cresyl sulfate ,uremic toxins ,indoxyl sulfate - Abstract
Chronic kidney disease (CKD) induces several systemic effects, including the accumulation and production of uremic toxins responsible for the activation of various harmful processes. Gut dysbiosis has been widely described in CKD patients, even in the early stages of the disease. The abundant discharge of urea and other waste substances into the gut favors the selection of an altered intestinal microbiota in CKD patients. The prevalence of bacteria with fermentative activity leads to the release and accumulation in the gut and in the blood of several substances, such as p-Cresol (p-C), Indoxyl Sulfate (IS) and p-Cresyl Sulfate (p-CS). Since these metabolites are normally eliminated in the urine, they tend to accumulate in the blood of CKD patients proportionally to renal impairment. P-CS, IS and p-C play a fundamental role in the activation of various pro-tumorigenic processes, such as chronic systemic inflammation, the increase in the production of free radicals and immune dysfunction. An up to two-fold increase in the incidence of colon cancer development in CKD has been reported in several studies, although the pathogenic mechanisms explaining this compelling association have not yet been described. Based on our literature review, it appears likely the hypothesis of a role of p-C, IS and p-CS in colon cancer development and progression in CKD patients.
- Published
- 2023
7. Fluorescent nanodiamonds as innovative delivery systems for MiR-34a replacement in breast cancer
- Author
-
Abate, Marianna, Lombardi, Angela, Luce, Amalia, Porru, Manuela, Leonetti, Carlo, Bocchetti, Marco, Campani, Virginia, De Rosa, Giuseppe, Graziano, Sossio Fabio, Nele, Valeria, Cardile, Francesco, Marino, Federica Zito, Franco, Renato, Ronchi, Andrea, Scrima, Marianna, Sperlongano, Rossella, Alfano, Roberto, Misso, Gabriella, Amler, Evzen, Caraglia, Michele, Zappavigna, Silvia, Abate, Marianna, Lombardi, Angela, Luce, Amalia, Porru, Manuela, Leonetti, Carlo, Bocchetti, Marco, Campani, Virginia, De Rosa, Giuseppe, Graziano, Sossio Fabio, Nele, Valeria, Cardile, Francesco, Marino, Federica Zito, Franco, Renato, Ronchi, Andrea, Scrima, Marianna, Sperlongano, Rossella, Alfano, Roberto, Misso, Gabriella, Amler, Evzen, Caraglia, Michele, and Zappavigna, Silvia
- Published
- 2023
8. The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
- Author
-
Valerio Nardone, Caterina Romeo, Emma D’Ippolito, Pierpaolo Pastina, Maria D’Apolito, Luigi Pirtoli, Michele Caraglia, Luciano Mutti, Giovanna Bianco, Antonella Consuelo Falzea, Rocco Giannicola, Antonio Giordano, Pierosandro Tagliaferri, Claudia Vinciguerra, Isacco Desideri, Mauro Loi, Alfonso Reginelli, Salvatore Cappabianca, Pierfrancesco Tassone, Pierpaolo Correale, Nardone, V., Romeo, C., D'Ippolito, E., Pastina, P., D'Apolito, M., Pirtoli, L., Caraglia, M., Mutti, L., Bianco, G., Falzea, A. C., Giannicola, R., Giordano, A., Tagliaferri, P., Vinciguerra, C., Desideri, I., Loi, M., Reginelli, A., Cappabianca, S., Tassone, P., and Correale, P.
- Subjects
ALK inhibitors ,Central nervous system (CNS) ,Radiotherapy ,ALK rearrangement ,Brain metastases (BM) ,EGFR driver mutation ,Non-small cell lung cancer (NSCLC) ,Tyrosine kinase inhibitors (TKI) ,Radiology, Nuclear Medicine and imaging ,General Medicine ,ALK inhibitor - Abstract
Non-small cell lung cancer (NSCLC) is frequently complicated by central nervous system (CNS) metastases affecting patients’ life expectancy and quality. At the present clinical trials including neurosurgery, radiotherapy (RT) and systemic treatments alone or in combination have provided controversial results. CNS involvement is even more frequent in NSCLC patients with EGFR activating mutations or ALK rearrangement suggesting a role of target therapy in the upfront treatment in place of loco-regionals treatments (i.e. RT and/or surgery). So far clinical research has not explored the potential role of accurate brain imaging (i.e. MRI instead of the routine total-body contrast CT and/or PET/CT staging) to identify patients that could benefit of local therapies. Moreover, for patients who require concomitant RT there are no clear guidelines on the timing of intervention with respect to innovative precision medicine approaches with Tyrosine Kinase Inhibitors, ALK-inhibitors and/or immuno-oncological therapies. On this basis the present review describes the therapeutic strategies integrating medical and radiation oncology in patients with metastatic NSCLC (mNSCLC) adenocarcinoma with CNS involvement and EGFR activating mutations or ALK rearrangement.
- Published
- 2023
9. Molecular markers as a new tool for diagnostic and prognostic definition of type 2 diabetes mellitus
- Author
-
Abate, Marianna, Luce, Amalia, Cossu, Alessia M, Scrima, Marianna, Misso, Gabriella, Caraglia, Michele, Zappavigna, Silvia, Abate, Marianna, Luce, Amalia, Cossu, Alessia M, Scrima, Marianna, Misso, Gabriella, Caraglia, Michele, and Zappavigna, Silvia
- Subjects
General Medicine - Published
- 2023
10. A Proteomic Approach Reveals That miR-423-5p Modulates Glucidic and Amino Acid Metabolism in Prostate Cancer Cells
- Author
-
Amalia Luce, Angela Lombardi, Carmela Ferri, Silvia Zappavigna, Madhura S. Tathode, Amanda K. Miles, David J. Boocock, Jayakumar Vadakekolathu, Marco Bocchetti, Roberto Alfano, Rossella Sperlongano, Angela Ragone, Luigi Sapio, Vincenzo Desiderio, Silvio Naviglio, Tarik Regad, Michele Caraglia, Luce, Amalia, Lombardi, Angela, Ferri, Carmela, Zappavigna, Silvia, Tathode, Madhura S, Miles, Amanda K, Boocock, David J, Vadakekolathu, Jayakumar, Bocchetti, Marco, Alfano, Roberto, Sperlongano, Rossella, Ragone, Angela, Sapio, Luigi, Desiderio, Vincenzo, Naviglio, Silvio, Regad, Tarik, and Caraglia, Michele
- Subjects
prostate adenocarcinoma ,microRNA ,overall survival ,LNCaP ,non-coding RNA ,Organic Chemistry ,General Medicine ,MALAT1 ,proteomics ,metabolism ,target genes ,microtubule-associated protein 1B ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,Physical and Theoretical Chemistry ,Molecular Biology ,proteomic ,Spectroscopy - Abstract
Recently, we have demonstrated that miR-423-5p modulates the growth and metastases of prostate cancer (PCa) cells both in vitro and in vivo. Here, we have studied the effects of miR-423-5p on the proteomic profile in order to identify its intracellular targets and the affected pathways. Applying a quantitative proteomic approach, we analyzed the effects on the protein expression profile of miR-423-5p-transduced PCa cells. Moreover, a computational analysis of predicted targets of miR-423-5p was carried out by using several target prediction tools. Proteomic analysis showed that 63 proteins were differentially expressed in miR-423-5-p-transfected LNCaP cells if compared to controls. Pathway enrichment analysis revealed that stable overexpression of miR-423-5p in LNCaP PCa cells induced inhibition of glycolysis and the metabolism of several amino acids and a parallel downregulation of proteins involved in transcription and hypoxia, the immune response through Th17-derived cytokines, inflammation via amphorin signaling, and ion transport. Moreover, upregulated proteins were related to the S phase of cell cycle, chromatin modifications, apoptosis, blood coagulation, and calcium transport. We identified seven proteins commonly represented in miR-423-5p targets and differentially expressed proteins (DEPs) and analyzed their expression and influence on the survival of PCa patients from publicly accessible datasets. Overall, our findings suggest that miR-423-5p induces alterations in glucose and amino acid metabolism in PCa cells paralleled by modulation of several tumor-associated processes.
- Published
- 2022
- Full Text
- View/download PDF
11. Early evidence on vaccine effectiveness of COVID vaccines in PLWHA
- Author
-
Monica Sane Schepisi, Angela Meggiolaro, Andrea Siddu, Alessia Mammone, Sara Farina, Carolina Castagna, Anna Caraglia, Francesco Maraglino, Stefania Boccia, and Giovanni Rezza
- Subjects
Health (social science) ,Epidemiology ,Health Policy ,Public Health, Environmental and Occupational Health ,Medicine (miscellaneous) ,Health Informatics - Published
- 2023
12. Supplementary Figure S2 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Nikhil C. Munshi, Kenneth C. Anderson, Christian Rolfo, Mariateresa Fulciniti, Antonino Neri, Ida Perrotta, Michele Caraglia, Gabriella Misso, Ida Ferrandino, Maria Rita Pitari, Lavinia Raimondi, Enrica Romeo, Eugenio Morelli, Anna Maria Gullà, Maria Angelica Stamato, and Nicola Amodio
- Abstract
miR-29b overexpression and HDAC4-silencing affect MM cell autophagy
- Published
- 2023
13. Supplementary Figure S4 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Nikhil C. Munshi, Kenneth C. Anderson, Christian Rolfo, Mariateresa Fulciniti, Antonino Neri, Ida Perrotta, Michele Caraglia, Gabriella Misso, Ida Ferrandino, Maria Rita Pitari, Lavinia Raimondi, Enrica Romeo, Eugenio Morelli, Anna Maria Gullà, Maria Angelica Stamato, and Nicola Amodio
- Abstract
miR-29b inhibition impairs the effects of SAHA on NCI-H929 cell apoptosis and migration
- Published
- 2023
14. Supplementary Figure S1 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Nikhil C. Munshi, Kenneth C. Anderson, Christian Rolfo, Mariateresa Fulciniti, Antonino Neri, Ida Perrotta, Michele Caraglia, Gabriella Misso, Ida Ferrandino, Maria Rita Pitari, Lavinia Raimondi, Enrica Romeo, Eugenio Morelli, Anna Maria Gullà, Maria Angelica Stamato, and Nicola Amodio
- Abstract
miR-29b targets HDAC4 in SKMM1 cells
- Published
- 2023
15. Legends to Supplementary Table and Figures from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Nikhil C. Munshi, Kenneth C. Anderson, Christian Rolfo, Mariateresa Fulciniti, Antonino Neri, Ida Perrotta, Michele Caraglia, Gabriella Misso, Ida Ferrandino, Maria Rita Pitari, Lavinia Raimondi, Enrica Romeo, Eugenio Morelli, Anna Maria Gullà, Maria Angelica Stamato, and Nicola Amodio
- Abstract
Legends to Supplementary Table and Figures
- Published
- 2023
16. Supplementary Figure S5 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Nikhil C. Munshi, Kenneth C. Anderson, Christian Rolfo, Mariateresa Fulciniti, Antonino Neri, Ida Perrotta, Michele Caraglia, Gabriella Misso, Ida Ferrandino, Maria Rita Pitari, Lavinia Raimondi, Enrica Romeo, Eugenio Morelli, Anna Maria Gullà, Maria Angelica Stamato, and Nicola Amodio
- Abstract
In vivo effects of miR-29b plus SAHA in KMS11 xenografts
- Published
- 2023
17. Supplementary Table S1 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Nikhil C. Munshi, Kenneth C. Anderson, Christian Rolfo, Mariateresa Fulciniti, Antonino Neri, Ida Perrotta, Michele Caraglia, Gabriella Misso, Ida Ferrandino, Maria Rita Pitari, Lavinia Raimondi, Enrica Romeo, Eugenio Morelli, Anna Maria Gullà, Maria Angelica Stamato, and Nicola Amodio
- Abstract
In silico analysis of HDAC4-targeting by miR-29b
- Published
- 2023
18. Supplementary Figure S3 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Nikhil C. Munshi, Kenneth C. Anderson, Christian Rolfo, Mariateresa Fulciniti, Antonino Neri, Ida Perrotta, Michele Caraglia, Gabriella Misso, Ida Ferrandino, Maria Rita Pitari, Lavinia Raimondi, Enrica Romeo, Eugenio Morelli, Anna Maria Gullà, Maria Angelica Stamato, and Nicola Amodio
- Abstract
Analysis of apoptosis and autophagy triggered by SAHA and miR-29b mimics in MM cells
- Published
- 2023
19. Supplementary Figure 7 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Antonino Neri, Kenneth C. Anderson, Nikhil C. Munshi, Masood A. Shammas, Michele Caraglia, Manlio Ferrarini, Massimo Negrini, Marco Rossi, Vera Tomaino, Eugenio Morelli, Francesco Conforti, Annamaria Gullà, Maria E. Gallo Cantafio, Maria R. Pitari, Marta Lionetti, Umberto Foresta, Nicola Amodio, Emanuela Leone, and Maria T. Di Martino
- Abstract
PDF file - 106K, Systemic delivery of formulated miR34a mimics affects the growth of MM xenografts
- Published
- 2023
20. Supplementary Figure 5 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Antonino Neri, Kenneth C. Anderson, Nikhil C. Munshi, Masood A. Shammas, Michele Caraglia, Manlio Ferrarini, Massimo Negrini, Marco Rossi, Vera Tomaino, Eugenio Morelli, Francesco Conforti, Annamaria Gullà, Maria E. Gallo Cantafio, Maria R. Pitari, Marta Lionetti, Umberto Foresta, Nicola Amodio, Emanuela Leone, and Maria T. Di Martino
- Abstract
PDF file - 78K, Quantitative analysis of miR-34a levels in retrieved tumors
- Published
- 2023
21. Supplementary Methods from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Antonino Neri, Kenneth C. Anderson, Nikhil C. Munshi, Masood A. Shammas, Michele Caraglia, Manlio Ferrarini, Massimo Negrini, Marco Rossi, Vera Tomaino, Eugenio Morelli, Francesco Conforti, Annamaria Gullà, Maria E. Gallo Cantafio, Maria R. Pitari, Marta Lionetti, Umberto Foresta, Nicola Amodio, Emanuela Leone, and Maria T. Di Martino
- Abstract
PDF file - 164K, Cell culture methods, in vitro assays, in vivo models
- Published
- 2023
22. Data from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Antonino Neri, Kenneth C. Anderson, Nikhil C. Munshi, Masood A. Shammas, Michele Caraglia, Manlio Ferrarini, Massimo Negrini, Marco Rossi, Vera Tomaino, Eugenio Morelli, Francesco Conforti, Annamaria Gullà, Maria E. Gallo Cantafio, Maria R. Pitari, Marta Lionetti, Umberto Foresta, Nicola Amodio, Emanuela Leone, and Maria T. Di Martino
- Abstract
Purpose: Deregulated expression of miRNAs has been shown in multiple myeloma (MM). A promising strategy to achieve a therapeutic effect by targeting the miRNA regulatory network is to enforce the expression of miRNAs that act as tumor suppressor genes, such as miR-34a.Experimental Design: Here, we investigated the therapeutic potential of synthetic miR-34a against human MM cells in vitro and in vivo.Results: Either transient expression of miR-34a synthetic mimics or lentivirus-based miR-34a-stable enforced expression triggered growth inhibition and apoptosis in MM cells in vitro. Synthetic miR-34a downregulated canonic targets BCL2, CDK6, and NOTCH1 at both the mRNA and protein level. Lentiviral vector-transduced MM xenografts with constitutive miR-34a expression showed high growth inhibition in severe combined immunodeficient (SCID) mice. The anti-MM activity of lipidic-formulated miR-34a was further shown in vivo in two different experimental settings: (i) SCID mice bearing nontransduced MM xenografts; and (ii) SCID-synth-hu mice implanted with synthetic 3-dimensional scaffolds reconstituted with human bone marrow stromal cells and then engrafted with human MM cells. Relevant tumor growth inhibition and survival improvement were observed in mice bearing TP53-mutated MM xenografts treated with miR-34a mimics in the absence of systemic toxicity.Conclusions: Our findings provide a proof-of-principle that formulated synthetic miR-34a has therapeutic activity in preclinical models and support a framework for development of miR-34a–based treatment strategies in MM patients. Clin Cancer Res; 18(22); 6260–70. ©2012 AACR.
- Published
- 2023
23. Supplementary Figure 6 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Antonino Neri, Kenneth C. Anderson, Nikhil C. Munshi, Masood A. Shammas, Michele Caraglia, Manlio Ferrarini, Massimo Negrini, Marco Rossi, Vera Tomaino, Eugenio Morelli, Francesco Conforti, Annamaria Gullà, Maria E. Gallo Cantafio, Maria R. Pitari, Marta Lionetti, Umberto Foresta, Nicola Amodio, Emanuela Leone, and Maria T. Di Martino
- Abstract
PDF file - 111K, In vivo activity of miR-34a in RPMI-8226 xenografts
- Published
- 2023
24. Supplementary Figure 4 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
- Author
-
Pierfrancesco Tassone, Pierosandro Tagliaferri, Antonino Neri, Kenneth C. Anderson, Nikhil C. Munshi, Masood A. Shammas, Michele Caraglia, Manlio Ferrarini, Massimo Negrini, Marco Rossi, Vera Tomaino, Eugenio Morelli, Francesco Conforti, Annamaria Gullà, Maria E. Gallo Cantafio, Maria R. Pitari, Marta Lionetti, Umberto Foresta, Nicola Amodio, Emanuela Leone, and Maria T. Di Martino
- Abstract
PDF file - 108K, Effects induced by stable expression of miR-34a
- Published
- 2023
25. Self-assessment of empathy uncovers defective self-awareness in mild cognitive impairment
- Author
-
Davide Quaranta, Chiara Cerami, Naike Caraglia, Emanuele Maria Costantini, Sonia Di Tella, Maria Caterina Silveri, Stefano Cappa, Simona Gaudino, Camillo Marra, and Alessandra Dodich
- Subjects
mild cognitive impairment ,Neuropsychology and Physiological Psychology ,Settore M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICA ,social cognition ,Alzheimer's disease ,empathy ,self-awareness - Published
- 2023
26. Dalle immagini alle parole: una proposta di didattica ludica dell’italiano L2 con il silent book
- Author
-
Caraglia, Deborah
- Abstract
Di fronte al sempre più complesso panorama scolastico italiano, spesso fatto di classi multilingue, multiculturali e multilivello, uno dei bisogni che si avverte è quello di un percorso di sviluppo e potenziamento della lingua italiana rivolto agli studenti di origine straniera che sia un percorso di crescita e condivisione, utile e stimolante al tempo stesso, capace di motivare gli studenti. Da qui, il contributo presenta una proposta didattica che ricorre al metodo ludico e all’uso di uno strumento nuovo nello scenario scolastico italiano: il silent book., Italiano a scuola, Vol. 4 (2022)
- Published
- 2023
- Full Text
- View/download PDF
27. Polydatin Incorporated in Polycaprolactone Nanofibers Improves Osteogenic Differentiation
- Author
-
Stefania Lama, Amalia Luce, Giuseppe Bitti, Pilar Chacon-Millan, Annalisa Itro, Pasquale Ferranti, Giovanni D’Auria, Marcella Cammarota, Giovanni Francesco Nicoletti, Giuseppe Andrea Ferraro, Chiara Schiraldi, Michele Caraglia, Evzen Amler, Paola Stiuso, Lama, S., Luce, A., Bitti, G., Chacon-Millan, P., Itro, A., Ferranti, P., D'Auria, G., Cammarota, M., Nicoletti, G. F., Ferraro, G. A., Schiraldi, C., Caraglia, M., Amler, E., Stiuso, P., Lama, Stefania, Luce, Amalia, Bitti, Giuseppe, Chacon-Millan, Pilar, Itro, Annalisa, Ferranti, Pasquale, D'Auria, Giovanni, Cammarota, Marcella, Nicoletti, Giovanni Francesco, Ferraro, Giuseppe Andrea, Schiraldi, Chiara, Caraglia, Michele, Amler, Evzen, and Stiuso, Paola
- Subjects
osteosarcoma ,polydatin ,osteogenic differentiation ,mesenchymal stem cells ,polycaprolactone nanofibers ,Drug Discovery ,technology, industry, and agriculture ,Pharmaceutical Science ,Molecular Medicine ,equipment and supplies ,musculoskeletal system ,polycaprolactone nanofiber ,mesenchymal stem cell - Abstract
Polycaprolactone nanofibers are used as scaffolds in the field of tissue engineering for tissue regeneration or drug delivery. Polycaprolactone (PCL) is a biodegradable hydrophobic polyester used to obtain implantable nanostructures, which are clinically applicable due to their biological safety. Polydatin (PD), a glycosidic precursor of resveratrol, is known for its antioxidant, antitumor, antiosteoporotic, and bone regeneration activities. We aimed to use the osteogenic capacity of polydatin to create a biomimetic innovative and patented scaffold consisting of PCL-PD for bone tissue engineering. Both osteosarcoma cells (Saos-2) and mesenchymal stem cells (MSCs) were used to test the in vitro cytocompatibility of the PD-PCL scaffold. Reverse-phase (RP) HPLC was used to evaluate the timing release of PD from the PCL-PD nanofibers and the MTT assay, scanning electron microscopy, and alkaline phosphatase (ALP) activity were used to evaluate the proliferation, adhesion, and cellular differentiation in both osteosarcoma and human mesenchymal stem cells (MSCs) seeded on PD-PCL nanofibers. The proliferation of osteosarcoma cells (Saos-2) on the PD-PCL scaffold decreased when compared to cells grown on PLC nanofibers, whereas the proliferation of MSCs was comparable in both PCL and PD-PCL nanofibers. Noteworthy, after 14 days, the ALP activity was higher in both Saos-2 cells and MSCs cultivated on PD-PCL than on empty scaffolds. Moreover, the same cells showed a spindle-shaped morphology after 14 days when grown on PD-PCL as shown by SEM. In conclusion, we provide evidence that nanofibers appropriately coated with PD support the adhesion and promote the osteogenic differentiation of both human osteosarcoma cells and MSCs.
- Published
- 2022
28. Could PD-1/PDL1 immune checkpoints be linked to HLA signature?
- Author
-
Valerio Nardone, Rita Emilena Saladino, Pierosandro Tagliaferri, Rita Agostino, Luigi Pirtoli, Rocco Giannicola, Ciro Botta, Michele Caraglia, Pierpaolo Correale, Correale P., Saladino R.E., Nardone V., Giannicola R., Agostino R., Pirtoli L., Caraglia M., Botta C., Tagliaferri P., Correale, P., Saladino, R. E., Nardone, V., Giannicola, R., Agostino, R., Pirtoli, L., Caraglia, M., Botta, C., and Tagliaferri, P.
- Subjects
Drug-Related Side Effects and Adverse Reactions ,Programmed Cell Death 1 Receptor ,Immunology ,Antibodies, Monoclon al ,Human leukocyte antigen ,B7-H1 Antigen ,Immune system ,HLA Antigens ,irAE ,Neoplasms ,Humans ,Immunology and Allergy ,Medicine ,PD-1/PDL-1-blockade ,business.industry ,Antibodies, Monoclonal ,Biomarker ,Signature (logic) ,Haplotypes ,Oncology ,outcome ,Immunotherapy ,HLA allele ,Drug-Related Side Effects and Adverse Reaction ,business ,Biomarkers - Abstract
The outstanding clinical expansion of monoclonal antibodies (mAbs) to programmed cell death receptor-1 (PD-1) (nivolumab and pembrolizumab) and PD-1 ligand-1 (PDL-1) (atezolizumab, avelumab and durvalumab) has received an increasing level of interest regarding immunotherapy and multidrug combinations, for the treatment of a number of common human malignancies. Some patients treated with these agents receive remarkable benefits in term of quality of life, progression-free (PFS) and overall survival (OS). However, a significant percentage of these patients experience immune-related adverse events (irAEs), while others present with an ultra-rapid disease progression, defined as hyperprogression. Research in to the mechanisms related to these events is an active field of investigation worldwide, whose results are expected to provide new insights to design new combinations, to identify potentially responsive patients and to prevent irAEs’ occurrence
- Published
- 2019
29. Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review
- Author
-
Mariachiara Santorsola, Vincenzo Di Lauro, Guglielmo Nasti, Michele Caraglia, Maurizio Capuozzo, Francesco Perri, Marco Cascella, Gabriella Misso, Alessandro Ottaiano, Santorsola, M., Di Lauro, V., Nasti, G., Caraglia, M., Capuozzo, M., Perri, F., Cascella, M., Misso, G., and Ottaiano, A.
- Subjects
Cancer Research ,breast cancer ,non-small-cell lung cancer ,Oncology ,phase III studie ,colorectal cancer ,tumour burden - Abstract
Background: Randomised phase III clinical trials represent a methodological milestone to select effective drugs against metastatic cancers. In this context, and particularly in the efficacy assessment of biologic drugs, the initial metastatic tumour burden is a strong prognostic factor. Methods: A systematic literature review of randomised, phase III, first-line, clinical trials in metastatic breast, colorectal, and lung cancers, published from 2016 to 2021, was performed. Three groups of variables were collected: identity-, method- (including tumour burden assessment) and outcome-related. Results: Seventy trials were selected. A large portion of studies (41.4%) focused on the effects of biologic agents (signal inhibitors and immuno-therapies). A definition of low-burden disease based predominantly on the number of involved organs was reported in 28.6% of studies. No explicit reference to oligo-metastatic disease was found either in inclusion/exclusion criteria or in final descriptive data analyses. Disease extent, heterogeneously defined, was a stratification factor for randomisation in only 25.7% of studies. In two studies, a significant imbalance between arms in patients with low-burden disease was revealed. Conclusions: Attention to initial tumour burden in designing future clinical trials (including the harmonisation of definitions and the reporting of eventual oligo-metastatic disease, complete estimates of tumour volume, and its consideration as a stratification factor) should be increased.
- Published
- 2022
30. Impact of Epstein Barr Virus Infection on Treatment Opportunities in Patients with Nasopharyngeal Cancer
- Author
-
Francesco Perri, Francesco Sabbatino, Alessandro Ottaiano, Roberta Fusco, Michele Caraglia, Marco Cascella, Francesco Longo, Rosalia Anna Rega, Giovanni Salzano, Monica Pontone, Maria Luisa Marciano, Arianna Piccirillo, Massimo Montano, Morena Fasano, Fortunato Ciardiello, Giuseppina Della Vittoria Scarpati, and Franco Ionna
- Subjects
Cancer Research ,Oncology ,nasopharyngeal carcinoma ,tumor microenvironment ,Epstein Barr Virus ,check-point inhibitors ,immunotherapy ,tumor associated antigens - Abstract
Chemical, physical, and infectious agents may induce carcinogenesis, and in the latter case, viruses are involved in most cases. The occurrence of virus-induced carcinogenesis is a complex process caused by an interaction across multiple genes, mainly depending by the type of the virus. Molecular mechanisms at the basis of viral carcinogenesis, mainly suggest the involvement of a dysregulation of the cell cycle. Among the virus-inducing carcinogenesis, Epstein Barr Virus (EBV) plays a major role in the development of both hematological and oncological malignancies and importantly, several lines of evidence demonstrated that nasopharyngeal carcinoma (NPC) is consistently associated with EBV infection. Cancerogenesis in NPC may be induced by the activation of different EBV “oncoproteins” which are produced during the so called “latency phase” of EBV in the host cells. Moreover, EBV presence in NPC does affect the tumor microenvironment (TME) leading to a strongly immunosuppressed status. Translational implications of the above-mentioned statements are that EBV-infected NPC cells can express proteins potentially recognized by immune cells in order to elicit a host immune response (tumor associated antigens). Three immunotherapeutic approaches have been implemented for the treatment of NPC including active, adoptive immunotherapy, and modulation of immune regulatory molecules by use of the so-called checkpoint inhibitors. In this review, we will highlight the role of EBV infection in NPC development and analyze its possible implications on therapy strategies.
- Published
- 2023
31. Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives
- Author
-
Alessandro Ottaiano, Mariachiara Santorsola, Luisa Circelli, Anna Maria Trotta, Francesco Izzo, Francesco Perri, Marco Cascella, Francesco Sabbatino, Vincenza Granata, Marco Correra, Luca Tarotto, Salvatore Stilo, Francesco Fiore, Nicola Martucci, Antonello La Rocca, Carmine Picone, Paolo Muto, Valentina Borzillo, Andrea Belli, Renato Patrone, Edoardo Mercadante, Fabiana Tatangelo, Gerardo Ferrara, Annabella Di Mauro, Giosué Scognamiglio, Massimiliano Berretta, Maurizio Capuozzo, Angela Lombardi, Jérôme Galon, Oreste Gualillo, Ugo Pace, Paolo Delrio, Giovanni Savarese, Stefania Scala, Guglielmo Nasti, and Michele Caraglia
- Subjects
Cancer Research ,oligo-metastatic ,Oncology ,biomarkers ,genetics ,prognosis ,metastases ,radiotherapy - Abstract
Some cancer patients display a less aggressive form of metastatic disease, characterized by a low tumor burden and involving a smaller number of sites, which is referred to as “oligometastatic disease” (OMD). This review discusses new biomarkers, as well as methodological challenges and perspectives characterizing OMD. Recent studies have revealed that specific microRNA profiles, chromosome patterns, driver gene mutations (ERBB2, PBRM1, SETD2, KRAS, PIK3CA, SMAD4), polymorphisms (TCF7L2), and levels of immune cell infiltration into metastases, depending on the tumor type, are associated with an oligometastatic behavior. This suggests that OMD could be a distinct disease with specific biological and molecular characteristics. Therefore, the heterogeneity of initial tumor burden and inclusion of OMD patients in clinical trials pose a crucial methodological question that requires responses in the near future. Additionally, a solid understanding of the molecular and biological features of OMD will be necessary to support and complete the clinical staging systems, enabling a better distinction of metastatic behavior and tailored treatments.
- Published
- 2023
32. microRNA Detection via Nanostructured Biochips for Early Cancer Diagnostics
- Author
-
Sara Martino, Chiara Tammaro, Gabriella Misso, Michela Falco, Marianna Scrima, Marco Bocchetti, Ilaria Rea, Luca De Stefano, Michele Caraglia, Martino, S., Tammaro, C., Misso, G., Falco, M., Scrima, M., Bocchetti, M., Rea, I., De Stefano, L., and Caraglia, M.
- Subjects
microRNA ,nanoparticle ,nanostructured material ,Organic Chemistry ,biochip ,General Medicine ,biosensor ,optical detection ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,electrochemical detection ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy - Abstract
MicroRNA (miRNA) are constituted of approximately 22 nucleotides and play an important role in the regulation of many physiological functions and diseases. In the last 10 years, an increasing interest has been recorded in studying the expression profile of miRNAs in cancer. Real time-quantitative polymerase chain reaction (RT-qPCR), microarrays, and small RNA sequencing represent the gold standard techniques used in the last 30 years as detection methods. The advent of nanotechnology has allowed the fabrication of nanostructured biosensors which are widely exploited in the diagnostic field. Nanostructured biosensors offer many advantages: (i) their small size allows the construction of portable, wearable, and low-cost products; (ii) the large surface–volume ratio enables the loading of a great number of biorecognition elements (e.g., probes, receptors); and (iii) direct contact of the recognition element with the analyte increases the sensitivity and specificity inducing low limits of detection (LOD). In this review, the role of nanostructured biosensors in miRNA detection is explored, focusing on electrochemical and optical sensing. In particular, four types of nanomaterials (metallic nanoparticles, graphene oxide, quantum dots, and nanostructured polymers) are reported for both detection strategies with the aim to show their distinct properties and applications.
- Published
- 2023
33. Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry
- Author
-
Federica Zito Marino, Martina Amato, Andrea Ronchi, Iacopo Panarese, Franca Ferraraccio, Ferdinando De Vita, Giuseppe Tirino, Erika Martinelli, Teresa Troiani, Gaetano Facchini, Felice Pirozzi, Michele Perrotta, Pasquale Incoronato, Raffaele Addeo, Francesco Selvaggi, Francesco Saverio Lucido, Michele Caraglia, Giovanni Savarese, Roberto Sirica, Marika Casillo, Eva Lieto, Annamaria Auricchio, Francesca Cardella, Ludovico Docimo, Gennaro Galizia, Renato Franco, Zito Marino, Federica, Amato, Martina, Ronchi, Andrea, Panarese, Iacopo, Ferraraccio, Franca, De Vita, Ferdinando, Tirino, Giuseppe, Martinelli, Erika, Troiani, Teresa, Facchini, Gaetano, Pirozzi, Felice, Perrotta, Michele, Incoronato, Pasquale, Addeo, Raffaele, Selvaggi, Francesco, Lucido, Francesco Saverio, Caraglia, Michele, Savarese, Giovanni, Sirica, Roberto, Casillo, Marika, Lieto, Eva, Auricchio, Annamaria, Cardella, Francesca, Docimo, Ludovico, Galizia, Gennaro, and Franco, Renato
- Subjects
Cancer Research ,congenital, hereditary, and neonatal diseases and abnormalities ,Oncology ,microsatellite instability ,gastrointestinal cancers ,mismatch-repair-system-protein deficient ,mismatch-repair-system-protein patchy ,PCR ,neoplasms ,digestive system diseases - Abstract
Background: Microsatellite instability (MSI) is a predictive biomarker for immune checkpoint inhibitors. The main goal was to investigate the discordance between IHC and PCR/NGS for MSI testing in gastrointestinal cancers. Methods: Two series were analyzed through IHC for mismatch-repair-system proteins (MMRP) and PCR, with one series of 444 colorectal cancers (CRC) and the other of 176 gastric cancers (GC). All cases with discordant results between IHC and PCR were analyzed by NGS. IHC staining was evaluated as follows: proficient MMR (pMMR), with all MMR positive; deficient MMR (dMMR), with the loss of one heterodimer; and cases with the loss/patchy expression of one MMR (lo-paMMR). Cases with instability in at least two markers by PCR were MSI-high (MSI-H) and with instability in one marker, MSI-low (MSI-L). Cases without instability were evaluated as microsatellite-stable (MSS). Results: In the CRC cohort, 15 out of 444 cases were dMMR and 46 lo-paMMR. Among the 15 dMMR, 13 were MSI-H and 2 MSS. Among the 46 lo-paMMR, 13 were MSI-H and 33 were MSS. In the GC cohort, 13 out of 176 cases were dMMR and 6 cases lo-paMMR. Among the 13 dMMR, 12 were MSI-H and only 1 was MSS. All six lo-paMMR cases were MSS. All NGS results were in agreement with PCR. Conclusions: In clinical practice, MMR–IHC could be used as a screening test and additional molecular analysis is mandatory exclusively in cases carrying loss/patchy MMR-IHC.
- Published
- 2022
- Full Text
- View/download PDF
34. Characterization of KRAS Mutational Regression in Oligometastatic Patients
- Author
-
Ottaiano, Alessandro, de Vera d'Aragona, Roberta Penta, Trotta, Anna Maria, Santorsola, Mariachiara, Napolitano, Maria, Scognamiglio, Giosuè, Tatangelo, Fabiana, Grieco, Paolo, Zappavigna, Silvia, Granata, Vincenza, Perri, Francesco, Luce, Amalia, Savarese, Giovanni, Ianniello, Monica, Casillo, Marika, Petrillo, Nadia, Belli, Andrea, Izzo, Francesco, Nasti, Guglielmo, Caraglia, Michele, Scala, Stefania, Ottaiano, Alessandro, de Vera d'Aragona, Roberta Penta, Trotta, Anna Maria, Santorsola, Mariachiara, Napolitano, Maria, Scognamiglio, Giosuè, Tatangelo, Fabiana, Grieco, Paolo, Zappavigna, Silvia, Granata, Vincenza, Perri, Francesco, Luce, Amalia, Savarese, Giovanni, Ianniello, Monica, Casillo, Marika, Petrillo, Nadia, Belli, Andrea, Izzo, Francesco, Nasti, Guglielmo, Caraglia, Michele, and Scala, Stefania
- Subjects
HLA ,Proto-Oncogene Proteins p21(ras) ,Immunology ,Colonic Neoplasms ,Mutation ,KRAS ,cytotoxicity ,Immunology and Allergy ,Humans ,colorectal cancer ,oligo-metastatic disease ,Colorectal Neoplasms ,Prognosis - Abstract
BackgroundWe previously reported rare regressive genetic trajectories of KRAS pathogenic mutations as a specific hallmark of the genuine oligometastatic status in colorectal cancer (CRC).MethodsSurvival and prognostic impact of disease extent in 140 metastatic CRC patients were evaluated through the Kaplan–Meyer curves and the Log-Rank test. KRAS mutations were assessed through the Illumina NovaSeq 6000 platform and TruSight™ Oncology 500 kit. HLA typing was carried out by PCR with sequence-specific oligonucleotides. Lymphocyte densities in tumors were expressed as cells per square millimeter. NKs isolated and CD8+ from NK-depleted PBMCs were characterized through flow cytometry. CD107a externalization was evaluated as NKs/CD8 cytotoxicity toward human colon cancer cells HT29, SW620, HCT116, and LS174T carrying different KRAS mutations.ResultsThe oligometastatic status was a strong and independent variable for survival (HR: 0.08 vs. polymetastatic disease; 95% CI: 0.02–0.26; p KRAS was observed in 3 patients: patient (PAT)2, PAT5, and PAT8. PAT2 and PAT5 presented the highest levels of GrzB+ lymphocytes in the tumor cores of the metastases (120 ± 11.2 and 132 ± 12.2 cells/mm2, respectively). Six out of 9 patients (67%), including PAT2 and PAT5, expressed HLA-C7. Twopatients (PAT2 and PAT5) presented high CD3+/CD8+-dependent cytotoxicity against HLA-C7+ SW620 cells (p.G12V-mutated cells), which was consistent with their observed mutational regression (p.G12V/p.G13D in primary→p.G13D in metastatic tumor).ConclusionsWe provide evidence that CD3+/CD8+ lymphocytes from oligometastatic CRC patients display differential cytotoxicity against human colon cancer cells carrying KRAS mutations. This could provide an interesting basis for monitoring oligometastatic disease and developing future adoptive immunotherapies.
- Published
- 2022
35. Molecular Characterization of Cancer Associated Fibroblasts in Prostate Cancer
- Author
-
Giovanni Vitale, Michele Caraglia, Volker Jung, Jörn Kamradt, Davide Gentilini, Maria Teresa Di Martino, Alessandra Dicitore, Marianna Abate, Pierosandro Tagliaferri, Annalisa Itro, Matteo Ferro, Raffaele Balsamo, Marco De Sio, Gaetano Facchini, Luca Persani, Kai Schmitt, Matthias Saar, Michael Stöckle, Gerhard Unteregger, Silvia Zappavigna, Vitale, Giovanni, Caraglia, Michele, Jung, Volker, Kamradt, Jörn, Gentilini, Davide, Di Martino, Maria Teresa, Dicitore, Alessandra, Abate, Marianna, Tagliaferri, Pierosandro, Itro, Annalisa, Ferro, Matteo, Balsamo, Raffaele, De Sio, Marco, Facchini, Gaetano, Persani, Luca, Schmitt, Kai, Saar, Matthia, Stöckle, Michael, Unteregger, Gerhard, and Zappavigna, Silvia
- Subjects
non cancer-associated fibroblasts ,Cancer Research ,cell proliferation ,androgen signaling ,cancer-associated fibroblasts ,prostate cancer ,transcriptomic profiling ,Oncology ,cancer-associated fibroblast ,non cancer-associated fibroblast - Abstract
Cancers 14(12), 2943 (2022). doi:10.3390/cancers14122943 special issue: "Special Issue "Bio-Pathological Markers for the Diagnosis and Therapy of Cancers, Volume II" / Special Issue Editors: Dr. Lucia Salvatorelli, Guest Editor; Dr. Giuseppe Broggi, Guest Editor", Published by MDPI, Basel
- Published
- 2022
36. A New Source of Heterogeneity in Comparative and Translational Clinical Trials: The 'Border-Time' Bias
- Author
-
Mariachiara Santorsola, Michele Caraglia, Guglielmo Nasti, and Alessandro Ottaiano
- Subjects
Cancer Research ,Oncology - Abstract
The use of target-oriented drugs is profoundly changing the anti-cancer treatments. This new and expanding therapeutic context relies on the translation of biomarkers expression (laboratory testing) into clinical practice (treatment). Progression-free survival is a primary or co-primary endpoint in the large part of comparative clinical trials about biologic anti-cancer agents. Here, we describe the “border time” bias represented by specific time points and intervals that are an underestimated source of methodologic heterogeneity and can contribute to wrong evaluation of time-to-outcome. These issues are concentrated at the beginning (head: pre-screening and screening activities) and at the end (tail: modalities of disease reassessment) of the anti-cancer treatment and can represent a time-related bias. Reporting, and ideally shortening, the time spent in pre-screening and screening activities with synthetic and innovative methodological tools as well as more harmonized rules about timing of disease reassessment can contribute to reduce, or even prevent, this bias in clinical studies.
- Published
- 2022
37. The Art of Counseling in the Treatment of Head and Neck Cancer: Exploratory Investigation among Perceptions of Health Professionals in Southern Italy
- Author
-
Raffaele Addeo, Luca Pompella, Pasquale Vitale, Silvia Ileana Sara Fattoruso, Ilaria Di Giovanni, Francesco Perri, Michele Caraglia, Morena Fasano, and Raffaele Arigliani
- Subjects
Counseling ,Head and Neck Neoplasms ,Squamous Cell Carcinoma of Head and Neck ,Health Personnel ,metastatic squamous cell carcinoma of the head and neck ,counseling ,open communication ,Quality of Life ,Humans - Abstract
(1) Background: Recurrent and/or metastatic patients with head and neck squamous cell carcinoma show a poor prognosis, which has not changed significantly in 30 years. Preserving quality of life is a primary goal for this subset of patients; (2) Methods: A group of 19 physicians working in South Italy and daily involved in head and neck cancer care took an anonymous online survey aimed at revealing the level of knowledge and the application of communication techniques in daily patient care; (3) Results: Several specialists, 18 out 19 (95%), considered that patient participation in therapeutic choices is mandatory. The main obstacles to complete and reciprocate communication still consist of lack of time and staff, but also in the need for greater organization, which goes beyond the multidisciplinary strategy already used; (4) Conclusions: A greater impulse to training and updating on issues related to counseling can improve communication between the different clinicians involved in the treatment plan.
- Published
- 2022
- Full Text
- View/download PDF
38. SARS-COV-2 SURVEILLANCE IN LONG-TERM CARE FACILITIES: FEASIBILITY AND OUTCOMES OF AN ITALIAN WEEKLY-BASED SERVICE
- Author
-
C. Damiano, M. Sabbatucci, G. Onder, C. Lo Noce, M. Barbalace, A. Caraglia, and C. Giacomozzi
- Subjects
Microbiology (medical) ,Infectious Diseases ,General Medicine - Published
- 2023
39. Future directions and management of liquid biopsy in non-small cell lung cancer
- Author
-
Anna Grimaldi, Alessia Maria Cossu, Margherita Russo, Angela Lombardi, Alessandro Ottaiano, Marco Bocchetti, Marianna Scrima, Michele Caraglia, Cossu, Alessia Maria, Scrima, Marianna, Lombardi, Angela, Grimaldi, Anna, Russo, Margherita, Ottaiano, Alessandro, Caraglia, Michele, and Bocchetti, Marco
- Subjects
0301 basic medicine ,Oncology ,lcsh:Internal medicine ,medicine.medical_specialty ,Cancer therapy ,circulating cell-free tumor DNA ,03 medical and health sciences ,0302 clinical medicine ,Non-small cell lung cancer ,Internal medicine ,medicine ,molecular analysis ,Liquid biopsy ,lcsh:RC31-1245 ,Lung cancer ,liquid biopsy ,business.industry ,biomarkers ,Tumor therapy ,medicine.disease ,030104 developmental biology ,030220 oncology & carcinogenesis ,biomarker ,Non small cell ,business - Abstract
Lung cancer represents the world’s most common cause of cancer death. In recent years, we moved from a generic therapeutic strategy to a personalized approach, based on the molecular characterization of the tumor. In this view, liquid biopsy is becoming an important tool for assessing the progress or onset of lung disease. Liquid biopsy is a non-invasive procedure able to isolate circulating tumor cells, tumor educated platelets, exosomes and free circulating tumor DNA from body fluids. The characterization of these liquid biomarkers can help to choose the therapeutic strategy for each different case. In this review, the authors will analyze the main aspects of lung cancer and the applications currently in use focusing on the benefits associated with this approach for predicting the prognosis and monitoring the clinical conditions of lung cancer disease.
- Published
- 2020
40. Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer
- Author
-
Gerardo Botti, Angela Lombardi, Nicola Martucci, Giosuè Scognamiglio, Michele Caraglia, Giuseppina Liguori, Salvatore Tafuto, Monica Capozzi, Maria Napolitano, Manuela Buonanno, Fabienne Hermitte, Giovanni Savarese, Luigi D'Amore, Luisa Circelli, Alessandro Ottaiano, Anna Maria Trotta, Jérôme Galon, Fabiana Tatangelo, Annabella Di Mauro, Guglielmo Nasti, Francesco Perri, Antonello La Rocca, Stefania Scala, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), University of the Study of Campania Luigi Vanvitelli, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Columbia University Medical Center (CUMC), Columbia University [New York], Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Gestionnaire, Hal Sorbonne Université, Ottaiano, A., Circelli, L., Lombardi, A., Scala, S., Martucci, N., Galon, J., Buonanno, M., Scognamiglio, G., Botti, G., Hermitte, F., Savarese, G., D'Amore, L., Tatangelo, F., Di Mauro, A., Liguori, G., Trotta, A. M., Napolitano, M., Capozzi, M., Tafuto, S., Perri, F., La Rocca, A., Caraglia, M., and Nasti, G.
- Subjects
Male ,Cancer Research ,Lung Neoplasms ,Colorectal cancer ,[SDV]Life Sciences [q-bio] ,Immunology ,Disease ,Colorectal Neoplasm ,Predictive markers ,medicine.disease_cause ,Article ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Immune system ,medicine ,Tumor Microenvironment ,Humans ,Neoplasm Metastasis ,lcsh:QH573-671 ,Gene ,neoplasms ,030304 developmental biology ,0303 health sciences ,Lung ,business.industry ,lcsh:Cytology ,Point mutation ,Cell Biology ,medicine.disease ,Primary tumor ,digestive system diseases ,3. Good health ,Lung Neoplasm ,Neoplasm Metastasi ,[SDV] Life Sciences [q-bio] ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,Female ,KRAS ,Colorectal Neoplasms ,business ,Human - Abstract
Genetics and immunologic dynamics pushing the evolution of colorectal cancer (CRC) from the primary tumor to the metastases are largely unknown; cancer heterogeneity makes challenging both therapy and mechanistic studies. We selected patients developing CRC with lung-limited metastatic disease as only illness during their life in order to find any relevant genotype–phenotype relationship. Analysis of 523 cancer-relevant genes and of immune cells infiltration in primary and metastatic tissues revealed atypical genomic trajectories (TMB decrease, KRAS and SMAD4 regressive mutations), specific genetic events (ERBB2 point mutations) and scarce T-cell infiltration. These insights provide novel information in oligometastatic CRC biology and new perspectives for cancer monitoring and anti-cancer therapeutic strategies.
- Published
- 2020
41. Salivary mir-27b Expression in Oral Lichen Planus Patients: A Series of Cases and a Narrative Review of Literature
- Author
-
Hiromichi Kawasaki, Donatella Delle Cave, Angela Lombardi, Dario Di Stasio, Michele Caraglia, Marina Porcelli, Laura Mosca, Alberta Lucchese, Di Stasio, D., Mosca, L., Lucchese, A., Cave, D. D., Kawasaki, H., Lombardi, A., Porcelli, M., and Caraglia, M.
- Subjects
Micro Array ,Male ,Saliva ,MiR-27b ,Disease ,Real-Time Polymerase Chain Reaction ,medicine.disease_cause ,OLP ,Autoimmunity ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,stomatognathic system ,Drug Discovery ,Humans ,Medicine ,Oligonucleotide Array Sequence Analysis ,030304 developmental biology ,0303 health sciences ,business.industry ,Gene Expression Profiling ,General Medicine ,MicroRNA Expression Profile ,Middle Aged ,medicine.disease ,MicroRNAs ,stomatognathic diseases ,Real-time polymerase chain reaction ,030220 oncology & carcinogenesis ,Immunology ,Female ,Oral lichen planus ,MiRNA ,business ,Keratinocyte ,Lichen Planus, Oral - Abstract
Background: microRNAs play a critical role in auto-immunity, cell proliferation, differentiation and cell death. miRNAs are present in all biological fluids, and their expression is essential in maintaining regular immune functions and preventing autoimmunity, whereas miRNA dysregulation may be associated with the pathogenesis of autoimmune and inflammatory diseases. Oral lichen planus (OLP) is an inflammatory disease mediated by cytotoxic T cells attack against epithelial cells. The present study aims to perform a specific microRNA expression profile through the analysis of saliva in this disease. Methods: The study group was formed by five patients (mean age 62.8±1.98 years; 3 females/2 males) affected by oral lichen planus and control group by five healthy subjects (mean age 59.8 years±2.3; 3 females/ 2 males); using a low-density microarray analysis, we recorded a total of 98 differentially expressed miRNAs in the saliva of patients with oral lichen planus compared to the control group. The validation was performed for miR-27b with qRT-PCR in all saliva samples of oral lichen planus group. Results: 89 miRNAs were up-regulated and nine down-regulated. In details, levels of miR-21, miR- 125b, miR-203 and miR15b were increased (p Conclusions: Collecting saliva samples is a non-invasive procedure and is well accepted by all patients. microRNAs can be readily isolated and identified and can represent useful biomarkers of OLP.
- Published
- 2020
42. Overview on Molecular Biomarkers for Laryngeal Cancer: Looking for New Answers to an Old Problem
- Author
-
Michela Falco, Chiara Tammaro, Takashi Takeuchi, Alessia Maria Cossu, Giuseppe Scafuro, Silvia Zappavigna, Annalisa Itro, Raffaele Addeo, Marianna Scrima, Angela Lombardi, Filippo Ricciardiello, Carlo Irace, Michele Caraglia, Gabriella Misso, Falco, M., Tammaro, C., Takeuchi, T., Cossu, A. M., Scafuro, G., Zappavigna, S., Itro, A., Addeo, R., Scrima, M., Lombardi, A., Ricciardiello, F., Irace, C., Caraglia, M., Misso, G., and Irace, Carlo
- Subjects
Cancer Research ,lncRNA ,TME (tumor microenvironment) ,Oncology ,LSCC (laryngeal squamous cell carcinoma) ,epigenetic modification ,biomarker ,ctDNA ,CTC ,inflammatory marker ,miRNA - Abstract
Laryngeal squamous cell cancer (LSCC) accounts for almost 25–30% of all head and neck squamous cell cancers and is clustered according to the affected districts, as this determines distinct tendency to recur and metastasize. A major role for numerous genetic alterations in driving the onset and progression of this neoplasm is emerging. However, major efforts are still required for the identification of molecular markers useful for both early diagnosis and prognostic definition of LSCC that is still characterized by significant morbidity and mortality. Non-coding RNAs appear the most promising as they circulate in all the biological fluids allowing liquid biopsy determination, as well as due to their quick and characteristic modulation useful for non-invasive detection and monitoring of cancer. Other critical aspects are related to recent progress in circulating tumor cells and DNA detection, in metastatic status and chemo-refractoriness prediction, and in the functional interaction of LSCC with chronic inflammation and innate immunity. We review all these aspects taking into account the progress of the technologies in the field of next generation sequencing.
- Published
- 2022
43. Modeling Lung Carcinoids with Zebrafish Tumor Xenograft
- Author
-
Silvia Carra, Germano Gaudenzi, Alessandra Dicitore, Maria Celeste Cantone, Alice Plebani, Davide Saronni, Silvia Zappavigna, Michele Caraglia, Alessia Candeo, Andrea Bassi, Luca Persani, Giovanni Vitale, Carra, Silvia, Gaudenzi, Germano, Dicitore, Alessandra, Cantone, Maria Celeste, Plebani, Alice, Saronni, Davide, Zappavigna, Silvia, Caraglia, Michele, Candeo, Alessia, Bassi, Andrea, Persani, Luca, and Vitale, Giovanni
- Subjects
Lung Neoplasms ,sulfatinib ,lung carcinoid ,Carcinoid Tumor ,Catalysis ,Settore MED/13 - Endocrinologia ,atypical carcinoid ,Inorganic Chemistry ,angiogenesis ,lung carcinoids ,neuroendocrine tumors ,typical carcinoid ,zebrafish ,tumor xenograft ,metastasis ,Animals ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Lung ,Spectroscopy ,Neovascularization ,Pathologic ,Neovascularization, Pathologic ,Organic Chemistry ,Carcinoma ,angiogenesi ,General Medicine ,Computer Science Applications ,Carcinoma, Neuroendocrine ,Heterografts ,Zebrafish ,Neuroendocrine ,metastasi ,neuroendocrine tumor - Abstract
Lung carcinoids are neuroendocrine tumors that comprise well-differentiated typical (TCs) and atypical carcinoids (ACs). Preclinical models are indispensable for cancer drug screening since current therapies for advanced carcinoids are not curative. We aimed to develop a novel in vivo model of lung carcinoids based on the xenograft of lung TC (NCI-H835, UMC-11, and NCI-H727) and AC (NCI-H720) cell lines and patient-derived cell cultures inTg(fli1a:EGFP)y1zebrafish embryos. We exploited this platform to test the anti-tumor activity of sulfatinib. The tumorigenic potential of TC and AC implanted cells was evaluated by the quantification of tumor-induced angiogenesis and tumor cell migration as early as 24 h post-injection (hpi). The characterization of tumor-induced angiogenesis was performed in vivo and in real time, coupling the tumor xenograft with selective plane illumination microscopy on implanted zebrafish embryos. TC-implanted cells displayed a higher pro-angiogenic potential compared to AC cells, which inversely showed a relevant migratory behavior within 48 hpi. Sulfatinib inhibited tumor-induced angiogenesis, without affecting tumor cell spread in both TC and AC implanted embryos. In conclusion, zebrafish embryos implanted with TC and AC cells faithfully recapitulate the tumor behavior of human lung carcinoids and appear to be a promising platform for drug screening.
- Published
- 2022
44. Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?
- Author
-
Valerio Nardone, Pierpaolo Correale, Luciano Mutti, Isacco Desideri, Caterina Romeo, Pierpaolo Pastina, Pierosandro Tagliaferri, Michele Caraglia, Alfonso Reginelli, Luigi Pirtoli, Salvatore Cappabianca, Nardone, Valerio, Correale, Pierpaolo, Mutti, Luciano, Desideri, Isacco, Romeo, Caterina, Pastina, Pierpaolo, Tagliaferri, Pierosandro, Caraglia, Michele, Reginelli, Alfonso, Pirtoli, Luigi, and Cappabianca, Salvatore
- Subjects
Pulmonary and Respiratory Medicine ,Oncology - Published
- 2022
45. Clinical and Molecular Characteristics of Rare Malignant Tumors of Colon and Rectum
- Author
-
Alessandro Ottaiano, Mariachiara Santorsola, Francesco Perri, Ugo Pace, Bruno Marra, Marco Correra, Francesco Sabbatino, Marco Cascella, Nadia Petrillo, Monica Ianniello, Marika Casillo, Gabriella Misso, Paolo Delrio, Michele Caraglia, Guglielmo Nasti, Ottaiano, A., Santorsola, M., Perri, F., Pace, U., Marra, B., Correra, M., Sabbatino, F., Cascella, M., Petrillo, N., Ianniello, M., Casillo, M., Misso, G., Delrio, P., Caraglia, M., and Nasti, G.
- Subjects
Rare tumors ,General Immunology and Microbiology ,Genetic ,Colon ,NGS ,Rare tumor ,Genetics ,Rectum ,General Agricultural and Biological Sciences ,digestive system diseases ,General Biochemistry, Genetics and Molecular Biology - Abstract
The most frequent form of colorectal cancer is represented by adenocarcinoma being about 98% of tumor histological types. However, other rare histotypes can be found in colon and rectum (adenosquamous, goblet cell adenocarcinoma, lymphoma, medullary carcinoma, melanoma, mesenchymal, neuroendocrine, plasmacytoma, signet ring, squamous tumors). Altogether, these forms account for less than 2% of colorectal tumors. There are no specific diagnostic or therapeutic recommended approaches and most of the information available from literature derives from small and retrospective clinical series. In the present study, we provide a paramount and updated view on clinical and biologic characteristics of rare colorectal tumors.
- Published
- 2022
46. MicroRNAs’ Crucial Role in Salivary Gland Cancers’ Onset and Prognosis
- Author
-
Marco Bocchetti, Piera Grisolia, Federica Melisi, Maria Grazia Ferraro, Pietro De Luca, Angelo Camaioni, Michela Falco, Marianna Abate, Gabriella Misso, Roberto Alfano, Nunzio Accardo, Flavia Oliva, Alessia Maria Cossu, Michele Caraglia, Marianna Scrima, Filippo Ricciardiello, Bocchetti, M., Grisolia, P., Melisi, F., Ferraro, M. G., De Luca, P., Camaioni, A., Falco, M., Abate, M., Misso, G., Alfano, R., Accardo, N., Oliva, F., Cossu, A. M., Caraglia, M., Scrima, M., and Ricciardiello, F.
- Subjects
salivary gland cancer ,Cancer Research ,diagnosi ,Oncology ,microRNA ,biomarker ,prognosi - Abstract
Salivary gland cancer (SGC) is an uncommon and heterogeneous disease that accounts for around 8.5% of all head and neck cancers. MicroRNAs (miRNAs) consist of a class of highly conserved, short, single-stranded segments (18–25 nucleotides) of noncoding RNA that represent key gene-transcription regulators in physiological and pathological human conditions. However, their role in SGC development and progression is not completely clear. This review aims to compile and summarize the recent findings on the topic, focusing on the prognostic and diagnostic value of the major modulated and validated microRNAs in SGC. Their differential expression could possibly aid the clinician in delivering an early diagnosis, therapeutic strategy and precision medicine.
- Published
- 2022
47. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer
- Author
-
Ferri, C, Di Biase, A, Bocchetti, M, Zappavigna, S, Wagner, S, Le Vu, P, Luce, A, Cossu, AM, Vadakekolathu, J, Miles, A, Boocock, DJ, Robinson, A, Schwerdtfeger, M, Tirino, V, Papaccio, F, Caraglia, M, Regad, T, Desiderio, V, Ferri, C., Di Biase, A., Bocchetti, M., Zappavigna, S., Wagner, S., Le Vu, P., Luce, A., Cossu, A. M., Vadakekolathu, J., Miles, A., Boocock, D. J., Robinson, A., Schwerdtfeger, M., Tirino, V., Papaccio, F., Caraglia, M., Regad, T., and Desiderio, V.
- Subjects
Male ,Cancer Research ,Molecular biology ,lncRNAs ,Mice, Nude ,Transfection ,miR-423-5p ,Mice ,Malat-1 ,lncRNA ,Animals ,Humans ,Cellular biology ,Neoplasm Metastasis ,RC254-282 ,miRNA ,Cell Proliferation ,Cancer ,Research ,Prostate ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prostatic Neoplasms ,Gene expression ,miRNAs ,MicroRNAs ,Oncology - Abstract
Background The long non-coding RNA (lncRNA), MALAT1, plays a key role in the development of different cancers, and its expression is associated with worse prognosis in patients. However, its mechanism of action and its regulation are not well known in prostate cancer (PCa). A general mechanism of action of lncRNAs is their interaction with other epigenetic regulators including microRNAs (miRNAs). Methods Using lentiviral stable miRNA transfection together with cell biology functional assays and gene expression/target analysis, we investigated the interaction between MALAT1 and miR-423-5p, defined as a target with in silico prediction analysis, in PCa. Results Through bioinformatic analysis of data available from TCGA, we have found that MALAT1 expression correlates with high Gleason grade, metastasis occurrence, and reduced survival in PCa patients. These findings were validated on a TMA of PCa showing a significant correlation between MALAT1 expression with both stage and grading. We report that, in PCa cells, MALAT1 expression and activity is regulated by miR-423-5p that binds MALAT1, downregulates its expression and inhibits its activity in promoting proliferation, migration, and invasion. Using NanoString analysis, we unraveled downstream cell pathways that were affected by miR-423-5p expression and MALAT1 downregulation and identified several alterations in genes that are involved in metastatic response and angiogenic pathways. In addition, we showed that the overexpression of miR-423-5p increases survival and decreases metastases formation in a xenograft mouse model. Conclusions We provide evidence on the role of MALAT1 in PCa tumorigenesis and progression. Also, we identify a direct interaction between miR-423-5p and MALAT1, which results in the suppression of MALAT1 action in PCa.
- Published
- 2022
48. BK Virus Infection and BK-Virus-Associated Nephropathy in Renal Transplant Recipients
- Author
-
Margherita Borriello, Diego Ingrosso, Alessandra Fortunata Perna, Angela Lombardi, Paolo Maggi, Lucia Altucci, Michele Caraglia, Borriello, Margherita, Ingrosso, Diego, Perna, Alessandra Fortunata, Lombardi, Angela, Maggi, Paolo, Altucci, Lucia, and Caraglia, Michele
- Subjects
Polyomavirus Infections ,Tumor Virus Infections ,BK Virus ,Genetics ,Humans ,Kidney Diseases ,Kidney ,Kidney Transplantation ,Immunosuppressive Agents ,Genetics (clinical) - Abstract
Poliomavirus BK virus (BKV) is highly infective, causing asymptomatic infections during childhood. After the initial infection, a stable state of latent infection is recognized in kidney tubular cells and the uroepithelium with negligible clinical consequences. BKV is an important risk factor for BKV-associated diseases, and, in particular, for BKV-associated nephropathy (BKVN) in renal transplanted recipients (RTRs). BKVN affects up to 10% of renal transplanted recipients, and results in graft loss in up to 50% of those affected. Unfortunately, treatments for BK virus infection are restricted, and there is no efficient prophylaxis. In addition, consequent immunosuppressive therapy reduction contributes to immune rejection. Increasing surveillance and early diagnosis based upon easy and rapid analyses are resulting in more beneficial outcomes. In this report, the current status and perspectives in the diagnosis and treatment of BKV in RTRs are reviewed.
- Published
- 2022
49. Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis
- Author
-
Francesco Iovino, Anna Diana, Francesca Carlino, Franca Ferraraccio, Giuliano Antoniol, Francesca Fisone, Alessandra Perrone, Federica Zito Marino, Iacopo Panarese, Madhura S. Tathode, Michele Caraglia, Gianluca Gatta, Roberto Ruggiero, Simona Parisi, Ferdinando De Vita, Fortunato Ciardiello, Ludovico Docimo, Michele Orditura, Iovino, Francesco, Diana, Anna, Carlino, Francesca, Ferraraccio, Franca, Antoniol, Giuliano, Fisone, Francesca, Perrone, Alessandra, Zito Marino, Federica, Panarese, Iacopo, Tathode, Madhura S, Caraglia, Michele, Gatta, Gianluca, Ruggiero, Roberto, Parisi, Simona, De Vita, Ferdinando, Ciardiello, Fortunato, Docimo, Ludovico, and Orditura, Michele
- Subjects
biomarkers ,early breast cancer ,hepatocyte growth factor receptor ,c-MET ,biomarker ,General Medicine - Abstract
Introduction: The mesenchymal-epithelial transition factor (c-MET) receptor is overexpressed in about 14–54% of invasive breast cancers, but its prognostic value in clinical practice is still unclear. Methods: In order to investigate the relationship between c-MET expression levels and prognosis, we retrospectively reviewed the clinical features and outcomes of 105 women with estrogen receptor positive HER2 negative (ER+/HER2-) resected breast cancer. We used the Kaplan Meier method to estimate Disease Free Survival (DFS) and Breast Cancer Specific Survival (BCSS) in the subgroups of patients with high (≥50%) and low (
- Published
- 2022
50. Hybrid Self-Assembling Nanoparticles Encapsulating Zoledronic Acid: A Strategy for Fostering Their Clinical Use
- Author
-
Marianna Abate, Lorena Scotti, Valeria Nele, Michele Caraglia, Marco Biondi, Giuseppe De Rosa, Carlo Leonetti, Virginia Campani, Silvia Zappavigna, Manuela Porru, Abate, Marianna, Scotti, Lorena, Nele, Valeria, Caraglia, Michele, Biondi, Marco, De Rosa, Giuseppe, Leonetti, Carlo, Campani, Virginia, Zappavigna, Silvia, Porru, Manuela, and DE ROSA, Giuseppe
- Subjects
scale-up ,Sucrose ,bisphosphonate ,Diphosphonates ,Organic Chemistry ,glioblastoma ,lyophilization ,Trehalose ,General Medicine ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,Mice ,zoledronic acid ,Freeze Drying ,Animals ,Nanoparticles ,self-assembling nanoparticles ,bisphosphonates ,differential scanning calorimetry ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy ,self-assembling nanoparticle - Abstract
Self-assembling nanoparticles (SANPs) promise an effective delivery of bisphosphonates or microRNAs in the treatment of glioblastoma (GBM) and are obtained through the sequential mixing of four components immediately before use. The self-assembling approach facilitates technology transfer, but the complexity of the SANP preparation protocol raises significant concerns in the clinical setting due to the high risk of human errors during the procedure. In this work, it was hypothesized that the SANP preparation protocol could be simplified by using freeze-dried formulations. An in-depth thermodynamic study was conducted on solutions of different cryoprotectants, namely sucrose, mannitol and trehalose, to test their ability to stabilize the produced SANPs. In addition, the ability of SANPs to deliver drugs after lyophilization was assessed on selected formulations encapsulating zoledronic acid in vitro in the T98G GBM cell line and in vivo in an orthotopic mouse model. Results showed that, after lyophilization optimization, freeze-dried SANPs encapsulating zoledronic acid could retain their delivery ability, showing a significant inhibition of T98G cell growth both in vitro and in vivo. Overall, these results suggest that freeze-drying may help boost the industrial development of SANPs for the delivery of drugs to the brain.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.